Phio Pharmaceuticals Corp.
PHIO
$1.98
-$0.16-7.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 2.78M | 2.80M | 3.96M | 4.01M | 5.00M |
| Gross Profit | -2.78M | -2.80M | -3.96M | -4.01M | -5.00M |
| SG&A Expenses | 3.74M | 3.82M | 3.84M | 3.96M | 4.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.39M | 7.49M | 8.67M | 9.31M | 10.70M |
| Operating Income | -7.39M | -7.49M | -8.67M | -9.31M | -10.70M |
| Income Before Tax | -7.15M | -7.42M | -8.68M | -9.38M | -10.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.15 | -7.42 | -8.68 | -9.38 | -10.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.15M | -7.42M | -8.68M | -9.38M | -10.83M |
| EBIT | -7.39M | -7.49M | -8.67M | -9.31M | -10.70M |
| EBITDA | -7.39M | -7.47M | -8.65M | -9.26M | -10.64M |
| EPS Basic | -10.82 | -15.06 | -23.77 | -33.43 | -57.58 |
| Normalized Basic EPS | -6.76 | -9.18 | -14.62 | -20.66 | -35.75 |
| EPS Diluted | -10.82 | -15.06 | -23.77 | -33.43 | -57.58 |
| Normalized Diluted EPS | -6.76 | -9.18 | -14.62 | -20.66 | -35.75 |
| Average Basic Shares Outstanding | 3.15M | 2.34M | 1.62M | 1.31M | 924.50K |
| Average Diluted Shares Outstanding | 3.15M | 2.34M | 1.62M | 1.31M | 924.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |